4//SEC Filing
Toland Mark J 4
Accession 0001387131-19-008129
CIK 0001528557other
Filed
Oct 30, 8:00 PM ET
Accepted
Oct 31, 4:50 PM ET
Size
17.8 KB
Accession
0001387131-19-008129
Insider Transaction Report
Form 4
Toland Mark J
DirectorPresident and CEO
Transactions
- Disposition to Issuer
Non-qualified stock option (right to buy)
2019-10-29$2.82/sh−7,136,049$20,123,658→ 0 totalExercise: $1.46Exp: 2026-03-06→ Common Stock (7,136,049 underlying) - Disposition to Issuer
Non-qualified stock option (right to buy)
2019-10-29$3.58/sh−297,335$1,062,973→ 0 totalExercise: $0.70From: 2016-12-01Exp: 2026-11-30→ Common Stock (297,335 underlying) - Disposition to Issuer
Non-qualified stock option (right to buy)
2019-10-29$3.58/sh−297,335$1,062,973→ 0 totalExercise: $0.70From: 2017-06-22Exp: 2026-11-30→ Common Stock (297,335 underlying) - Disposition to Issuer
Non-qualified stock option (right to buy)
2019-10-29$2.82/sh−297,335$838,485→ 0 totalExercise: $1.46From: 2016-12-01Exp: 2026-03-06→ Common Stock (297,335 underlying) - Disposition to Issuer
Non-qualified stock option (right to buy)
2019-10-29$3.58/sh−297,335$1,062,973→ 0 totalExercise: $0.70From: 2017-05-17Exp: 2026-11-30→ Common Stock (297,335 underlying) - Disposition to Issuer
Non-qualified stock option (right to buy)
2019-10-29$3.53/sh−5,183,322$18,296,608→ 0 totalExercise: $0.75Exp: 2028-05-31→ Common Stock (5,183,322 underlying)
Footnotes (5)
- [F1]On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger").
- [F2]The option vested in full upon the Board's determination that Mr. Toland achieved the required performance criteria.
- [F3]At the effective time of the Merger (the "Effective Time"), which occurred on October 29, 2019, each outstanding and unexercised option to purchase shares of the Issuer's common stock automatically converted into the right to receive a cash payment equal to the product of (i) the excess, if any, of $4.28 over the per share exercise price of such option, and (ii) the number of shares of the Issuer's common stock subject to such option as of the Effective Time, without interest and net of any applicable withholding taxes.
- [F4]This option provided for vesting over a period of four years, with the first 25% vesting on March 7, 2017 and the remaining 75% vesting in 36 equal monthly installments beginning on April 7, 2017.
- [F5]This option provided for vesting on the date of certification by the Compensation Committee of the Board of the achievement of certain performance milestones, provided Mr. Toland was providing services to the Issuer or its affiliates on the date of such achievement.
Documents
Issuer
Corindus Vascular Robotics, Inc.
CIK 0001528557
Entity typeother
Related Parties
1- filerCIK 0001668033
Filing Metadata
- Form type
- 4
- Filed
- Oct 30, 8:00 PM ET
- Accepted
- Oct 31, 4:50 PM ET
- Size
- 17.8 KB